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Abstract
Background: Previous studies have indicated that a recently described anaerobic bacterium,
Atopobium vaginae is associated with bacterial vaginosis (BV). Thus far the four isolates of this
fastidious micro-organism were found to be highly resistant to metronidazole and susceptible for
clindamycin, two antibiotics preferred for the treatment of BV.
Methods: Nine strains of Atopobium vaginae, four strains of Gardnerella vaginalis, two strains of
Lactobacillus iners and one strain each of Bifidobacterium breve, B. longum, L. crispatus, L. gasseri and L.
jensenii were tested against 15 antimicrobial agents using the Etest.
Results: All nine strains of A. vaginae were highly resistant to nalidixic acid and colistin while being
inhibited by low concentrations of clindamycin (range: < 0.016 µg/ml), rifampicin (< 0.002 µg/ml),
azithromycin (< 0.016 – 0.32 µg/ml), penicillin (0.008 – 0.25 µg/ml), ampicillin (< 0.016 – 0.94 µg/
ml), ciprofloxacin (0.023 – 0.25 µg/ml) and linezolid (0.016 – 0.125 µg/ml). We found a variable
susceptibility for metronidazole, ranging from 2 to more than 256 µg/ml. The four G. vaginalis
strains were also susceptible for clindamycin (< 0.016 – 0.047 µg/ml) and three strains were
susceptible to less than 1 µg/ml of metronidazole. All lactobacilli were resistant to metronidazole
(> 256 µg/ml) but susceptible to clindamycin (0.023 – 0.125 µg/ml).
Conclusion: Clindamycin has higher activity against G. vaginalis and A. vaginae than metronidazole,
but not all A. vaginae isolates are metronidazole resistant, as seemed to be a straightforward
conclusion from previous studies on a more limited number of strains.
Background
Bacterial vaginosis is considered a common vaginal disor-
der in women of reproductive age. Whereas normal vagi-
nal microflora consists of lactobacilli, especially L.
crispatus [1-4], the disturbed vaginal microflora is charac-
terized by the overgrowth of Gardnerella vaginalis and
anaerobic bacteria such as Mobiluncus spp., Mycoplasma
hominis and Prevotella spp. Recently several research
groups showed – by means of cloning of the 16S rRNA-
gene [3,5], by Terminal Restriction Fragment Length Pol-
ymorphism analysis of the 16S rRNA gene (T-RFLP) [6,7],
by specific PCR [5,8,9], by Denaturing Gradient Gel Elec-
trophoresis of the 16S rRNA gene (DGGE) [10] and by
FISH [3,11] – that a previously unrecognized organism,
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vaginosis and with Gardnerella vaginalis.
During the last decade, the interest for bacterial vaginosis
increased because of reports of adverse sequelae of this
disorder, such as preterm birth [12-14], pelvic inflamma-
tory disease [15,16] and postpartum endometritis [17]. In
addition, several publications showed that an altered vag-
inal microflora is linked to an increased susceptibility to
the acquisition of HIV [18,19] and other sexually trans-
mitted infectious agents such as Neisseria gonorrhoeae and
Chlamydia trachomatis [18,20].
The severity of the consequences of such sequelae asks for
an adequate treatment of bacterial vaginosis. Currently
the preferred antibiotic treatment regimen consists of clin-
damycin or metronidazole (oral or intravaginal). Recur-
rence rates of up to 30% within 3 months after treatment
have been reported [21,22]. This recurrence might be due
to the survival of metronidazole or clindamycin resistant
bacteria in the vagina, although Beigi et al. [23] showed
recently that less than one percent of the cultivable vaginal
anaerobic bacteria is resistant to metronidazole.
Another possible explanation might be the presence of
some fastidious to unculturable, metronidazole resistant
organism, a role for which A. vaginae is a likely candidate,
since Geißdörfer et al. [24] and Ferris et al. [10] reported
an MIC of > 32 µg/ml for metronidazole for the four iso-
lates that were tested.
Here, we studied the susceptibility of nine other A. vaginae
isolates for 15 antimicrobial agents by using the Etest and
for comparison we included a limited number of other
important vaginal bacteria such as lactobacilli, G. vaginalis
and bifidobacteria and we compared our results with
those of previously published articles.
Methods
Nine strains of Atopobium vaginae, four strains of Gard-
nerella vaginalis, two strains of Lactobacillus iners and one
strain each of Bifidobacterium breve, B. longum, Lactobacillus
crispatus, L. gasseri and L. jensenii were tested against 15
antibiotics (ampicillin, azithromycin, bacitracin, cefurox-
ime, ciprofloxacin, clindamycin, colistin, doxycycline,
kanamycin, linezolid, metronidazole, nalidixic acid, pen-
icillin, rifampicin and vancomycin) [see Additional file
1]. Six strains of A. vaginae (CCUG 42099, CCUG 44116,
CCUG 44258, CCUG 38953T, CCUG 44125, CCUG
44061) were kindly provided by the Culture Collection of
Göteborg (Sweden). The other strains were obtained from
studies by cultivating vaginal samples (with informed
consent) and identified by tDNA-PCR and 16S rRNA gene
sequencing [4].
Strains were cultivated anaerobically using the GasPak
anaerobic envelope system (Becton Dickinson, Erembod-
egem, Belgium) at 37°C on Trypticase Soy Agar (TSA) + 5
% sheep blood (Becton Dickinson). Epsilometer tests
(Etest AB Biodisk, Solna, Sweden) were used to determine
the minimal inhibitory concentrations (MIC). An inocu-
lum taken from TSA + 5% sheep blood was suspended in
0.5 ml of physiological water and adjusted to the turbidity
of a 1 McFarland standard. Before inoculating the plates
and testing for metronidazole, plates were anaerobically
incubated during 24 h. After application of the epsilom-
eter, test plates were anaerobically incubated at 37°C. The
inhibitory concentration was defined as the value on the
test strip scale at which the inhibition zone intersected the
strip edge, according to the manufacturers' instructions.
MIC-values were read after 48 h for G. vaginalis, Lactobacil-
lus spp. and Bifidobacterium spp. and after 72 h for A. vagi-
nae.
Results and discussion
Value and reproducibility of Etest for MIC-determination 
of anaerobes
In this study we used the Etest for MIC-determination of
vaginal bacteria towards 15 antibiotics. Croco et al. [25]
concluded, from a study whereby the Etest was compared
with the reference agar dilution method, that the Etest was
a quantitatively accurate and reproducible method for
routinely testing the antimicrobial susceptibilities of
anaerobes, in particular of organisms associated with BV.
Discordances were reported only for clindamycin suscep-
tibility testing of lactobacilli and chloramphenicol suscep-
tibility testing of the Bacteroides fragilis group. Schieven et
al. [26] reported an agreement between the Etest and the
reference agar dilution method within 1 log2 dilution of
87.4% for clindamycin and 85.1% for metronidazole for
a total of 150 anaerobic isolates tested.
Antimicrobial susceptibility testing of Atopobium vaginae
The antibiotic susceptibility for ampicillin, azithromycin,
bacitracin, cefuroxime, ciprofloxacin, clindamycin, colis-
tin, doxycycline, kanamycin, linezolid, metronidazole,
nalidixic acid, penicillin, rifampicin and vancomycin
obtained for nine Atopobium vaginae isolates in this study
is listed in additional file 1 [see Additional file 1].
We focused our research on the antibiotic susceptibility
profile of Atopobium vaginae. In contrast to the results of
Ferris et al. [10] and Geißdörfer et al. [24], who reported
MIC-values of more than 32 µg/ml for all four A. vaginae
isolates tested (Table 1), we found a great variability in
susceptibility for metronidazole, ranging from 2 to more
than 256 µg/ml. When taking into account 16 µg/ml as
the breakpoint between sensitive and resistant (NCCLS
guidelines), only four out of 9 strains in our study could
be accounted as intermediately susceptible or resistant. AllPage 2 of 6
(page number not for citation purposes)
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more than 256 µg/ml for nalidixic acid and colistin while
being inhibited by low concentrations of clindamycin
(range: < 0.016 µg/ml), rifampicin (< 0.002 µg/ml), azi-
thromycin (< 0.016 – 0.32 µg/ml), penicillin (0.008 –
0.25 µg/ml), ampicillin (< 0.016 – 0.94 µg/ml), cipro-
floxacin (0.023 – 0.25 µg/ml) and linezolid (0.016 –
0.125 µg/ml) (Table 1).
We previously described the existence of a second geno-
type within A. vaginae. To this genotype belongs isolate
PB2003/189-T1-4, of which the 16S rRNA gene sequence
differs at 23 positions compared to the type strain, but is
identical to that of an isolate no longer in our collection
of which the sequence was submitted [Genbank:
AJ585206] [5]. This genotype 2 isolate showed a marked
difference only for azithromycin (i.e. MIC of 0.32 µg/ml)
with the other isolates (MIC of < 0.016 µg/ml).
Antimicrobial susceptibility testing of Gardnerella 
vaginalis
We tested 4 strains of Gardnerella vaginalis. By using the
Etest method in an anaerobic environment we found in
general slightly lower values for ampicillin (range: < 0.016
– 0.047 µg/ml), penicillin (0.004 – 0.047 µg/ml), cefuro-
xim (< 0.016 – 0.125 µg/ml) and rifampicin (0.5 – 0.75
µg/ml) (Table 1), compared to other publications
[25,27,28] [see Additional file 2]. The range of the MIC-
values of Gardnerella vaginalis for clindamycin (range: <
0.016 – 0.047 µg/ml), colistin (> 1024 µg/ml), doxycy-
cline (0.25 – 32 µg/ml), kanamycin (16 – 32 µg/ml), met-
ronidazole (0.75 – 16 µg/ml), nalidixic acid (> 256 µg/
ml) and vancomycin (0.125 – 0.38 µg/ml) is comparable
with other studies [25,27-31] [see Additional file 2]. G.
vaginalis is, according to NCCLS standards for anaerobic
bacteria, susceptible to ampicillin (range: < 0.016 – 0.047
µg/ml), penicillin (0.004 – 0.047 µg/ml) and azithromy-
cin (< 0.016 – 0.047 µg/ml). In 1993, Goldstein et al. [29]
reported that 20% of G. vaginalis strains were resistant to
metronidazole (MIC ≥ 16 µg/ml). In 2002, the same
group reported a resistance of 29% to metronidazole for
Table 1: Comparison of MIC-values as determined for Atopobium vaginae by Ferris et al. [8] and Geißdörfer et al. [24] and in this 
study.
This study Geißdörfer et al. [24]a Ferris et al. [8]b
Number of strains 9 1 3
Antimicrobial agent MIC50c Rangec MICc Rangec
Ampicillin 0.023 < 0.016 – 0.94 0.032
Ampicillin/sulbactam 0.06 – 0.25
Azitromycin < 0.016 < 0.016 – 0.32
Bacitracin 3 1 – 4
Cefoxitin 2 2
Ceftriaxone 0.5 – 2
Cefuroxime 0.125 0.016 – 0.25 0.19
Ciprofloxacin 0.064 0.023 – 0.25
Clindamycin < 0.016 < 0.016 < 0.015
Colistin > 1024 > 1024
Doxycyclin 0.38 0.19 – 0.75
Imipenem 0.016 < 0.015 – 0.5
Kanamycin 12 8 – 16
Linezolid 0.047 0.016 – 0.125 0.06 – 0.25
Meropenem < 0.015 – 0.5
Metronidazole 8 2 - > 256 >16 > 32
Moxifloxacin 0.06 – 1
Nalidixic acid > 256 > 256
Penicillin 0.094 0.008 – 0.25 0.125
Rifampicin < 0.002 < 0.002
Trovafloxacin < 0.015 – 2
Vancomycin 1.5 1 – 4
Legend
a. Tested with Etest and agar dilution method.
b. Tested with broth microdilution method for anaerobic bacteria with Brucella Broth supplemented with vitamin K (1 µg/ml), hemin (5 µg/ml) and 
laked horse blood (5%).
c. Data in µg/ml.Page 3 of 6
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tible.
Antimicrobial susceptibility testing of Lactobacillus spp
Most of the Lactobacillus spp. we tested show a low MIC-
value for ampicillin (range for all lactobacilli: 0.064 – 0.5
µg/ml), azithromycin (0.023 – 0.125 µg/ml), cefuroxim
(< 0.016 – 1 µg/ml), linezolid (0.19 – 1.5 µg/ml), penicil-
lin (0.047 – 0.19 µg/ml), rifampicin (0.016 – 2 µg/ml)
and vancomycin (0.38 – 1 µg/ml) [see Additional file 1].
All strains were resistant to metronidazole (range for all
lactobacilli: > 256 µg/ml). The strains of the species L.
crispatus, L. jensenii and L. gasseri were all highly resistant
to ciprofloxacin (range: > 32 µg/ml) in contrast to both L.
iners strains (range: 0.25 – 0.38 µg/ml).
The single strain of L. crispatus tested yielded a very low
MIC-value for clindamycin (< 0.016 µg/ml) and a high
MIC-value for rifampicin compared to the other lactoba-
cilli. The strain of L. gasseri tested showed comparable
results to those of previous publications [32,33] for clin-
damycin, metronidazole, penicillin and vancomycin [see
Additional file 2], indicating that this species is much
more resistant to clindamycin than L. crispatus.
All lactobacilli were resistant to metronidazole (> 256 µg/
ml) but susceptible for clindamycin (0.023 – 0.125 µg/
ml). There were no literature data to compare the suscep-
tibility of L. iners and L. jensenii for the antimicrobial
agents tested in this study.
Antimicrobial susceptibility testing of Bifidobacterium 
spp
Both of the tested Bifidobacterium strains are sensitive to a
low amount of ampicillin (B. longum: 0.25 µg/ml, B. breve:
0.38 µg/ml), azithromycin (B. longum: 0.064 µg/ml, B.
breve: 0.25 µg/ml), clindamycin (B. breve and B. longum: <
0.016 µg/ml), linezolid (B. longum: 0.25 µg/ml, B. breve:
0.38 µg/ml), penicillin (B. longum: 0.19 µg/ml, B. breve:
0.5 µg/ml), rifampicin (B. longum: 0.25 µg/ml, B. breve:
0.19 µg/ml) and vancomycin (B. longum: 0.38 µg/ml, B.
breve: 1 µg/ml) [see Additional file 1]. The strains tested
showed comparable results with previous publications
except for linezolid and kanamycin [see Additional file 2],
where we obtained a lower value than described [33-35].
Conclusion
Bacterial vaginosis is a polymicrobial disease and the
organisms involved are likely to be in symbiotic relation-
ship to each other for various metabolic requirements.
Antimicrobial treatment may affect susceptible members
of the consortia which may negatively alter the microen-
vironment for resistant organisms, such as A. vaginae and
G. vaginalis.
By knowing the antibiotic susceptibility of the vaginal
species it might be possible to develop new regimens for
the treatment of recurrent bacterial vaginosis.
For example, this study showed that metronidazole resist-
ance of A. vaginae is not an intrinsic feature. Further
research needs to make clear whether this metronidazole
resistance might be acquired by the presence and activa-
tion of nim-genes [36]. Metronidazole resistance up to
29% [30] has been described for G. vaginalis but mecha-
nisms are not yet clarified. Possibly this could be due to
the lack of nitroreductases necessary to produce the
hydroxymetabolite of metronidazole, which has stronger
antibiotic activity than the parent compound.
Lactobacilli are resistant to metronidazole and it has been
demonstrated that recolonistation of the vagina by H2O2-
producing lactobacilli after metronidazole treatment
occurs more frequently compared to clindamycin treat-
ment [37].
Clindamycin, which is frequently used as a treatment for
bacterial vaginosis, has indeed higher activity against G.
vaginalis and A. vaginae than metronidazole, but L. crispa-
tus is more susceptible to clindamycin than L. gasseri with
as a consequence that a regimen of clindamycin can
remove also the H2O2-producing lactobacilli from the
vaginal microflora (Table 2). Hydrogen peroxide produc-
tion is generally believed to be an important factor in the
preservation of a normal vaginal microflora [1], i.e. in
the build up of vaginal colonisation resistance. There-
Table 2: Overview of the MIC-value ranges for Atopobium vaginae 
and Gardnerella vaginalis for 15 antimicrobial agents.
Atopobium vaginae 
(n = 9)
Gardnerella vaginalis 
(n = 4)
Antimicrobial 
agent
Rangea Rangea
Ampicillin < 0.016 – 0.94 < 0.016 – 0.047
Azithromycin < 0.016 – 0.32 < 0.016 – 0.047
Bacitracin 1 – 4 0.75 – 2
Cefuroxim 0.016 – 0.25 < 0.016 – 0.125
Ciprofloxacin 0.023 – 0.25 0.75 – 2
Clindamycin < 0.016 < 0.016 – 0.047
Colistin > 1024 > 1024
Doxycycline 0.19 – 0.75 0.25 – 32
Kanamycin 8 – 16 16 – 32
Linezolid 0.016 – 0.125 0.125 – 0.19
Metronidazole 2 – 256 0.75 – 16
Nalidixic acid > 256 > 256
Penicillin 0.008 – 0.25 0.004 – 0.047
Rifampicin < 0.002 0.5 – 0.75
Vancomycin 1 – 4 0.125 – 0.38
Legend
a. Data in µg/ml.Page 4 of 6
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diminish the vaginal colonisation resistance. Moreover,
resistance to clindamycin seems to develop more readily
than resistance to metronidazole, as becomes apparent
from clinical studies comparing both antibiotics [23,37].
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